Full-Time
Technical Manager
Biologics
Posted on 8/20/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
No salary listed
Sligo, Ireland
In Person
Master's
 Biology & Biotech (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- A Master's degree in Chemistry, Biochemistry, Chemical Engineering, or a related field is required.
- At least 7 years of experience in a good manufacturing practice biologics manufacturing environment is required.
- Experience with technical transfers and new product introductions is essential.
- Proven leadership experience and the ability to inspire and motivate a diverse team are required.
- In-depth knowledge of clinical and commercial manufacturing, chemistry, manufacturing, and controls processes, analytical development, and chemistry, manufacturing, and controls technical lifecycle management is required.
- In-depth understanding of regulatory and quality requirements is required.
- Lead and support new product introduction activities for products, processes, and technology from early-stage development through process performance qualification.
- Lead and manage cross-functional teams across different skill sets and disciplines to deliver new product introductions.
- Collaborate with Process Development, Science and Technology, Quality, Manufacturing, Supply Chain, and ECM teams to transition new products from development to commercialization.
- Complete site-fit assessments for products from the company pipeline and ECM opportunities.
- Provide technical direction and oversight and coordinate support for new product introduction activities across the biological manufacturing area.
- Coordinate with internal and external program management to align new product introduction schedules.
- Ensure resource availability for new product introduction activities.
- Build and maintain innovation and continuous-improvement practices within the function.
- Provide leadership and mentoring for operations personnel during new product introduction activities.
- Collaborate with external parties to ensure engagement, alignment, and open communication throughout new product introduction activities.
- Influence the design and implementation of robust process-control strategies for process risk assessments.
- Generate product-transfer documentation confirming completion of product-transfer deliverables before application product-transfer stage-gate review.
- Provide technical input and review and approve documentation associated with new product introduction activities.
- Ensure ongoing compliance with current good manufacturing practice and environmental, health, and safety practices.
- Participate in new product introduction project gate reviews.
- Interface with internal auditors and external regulatory auditors as the subject matter expert for new products and technology transfers.
- Experience with antibody-drug conjugates and/or sterile fill-finish is advantageous but not essential.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
- FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
- WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.
What critics are saying
- HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
- The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
- Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.
What makes AbbVie unique
- SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
- Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
- Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.
AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals
AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.
UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -
AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.